Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators li...
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT03341494
- Locations
- 🇨🇳
Fujian Cancer Hospital Radiation Oncology Department, Fuzhou, Fujian, China
🇨🇳Fujian cancer hospital, Fuzhou, Fujian, China
Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- IRCCS Burlo Garofolo
- Target Recruit Count
- 9
- Registration Number
- NCT03221166
- Locations
- 🇮🇹
Gastroenterologia e Nutrizione Pediatrica, Azienda Ospedaliero Universitaria Meyer, Firenze, Toscana, Italy
🇮🇹IRCCS Burlo Garofolo, Trieste, Friuli Venezia Giulia, Italy
🇮🇹Fondazione MBBM , Azienda Ospedaliera San Gerardo - Università Milano Bicocca, Monza, Lombardia, Italy
The Therapeutic Effect of Thalidomide in RI
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2019-11-22
- Target Recruit Count
- 58
- Registration Number
- NCT03208413
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Guangzhou Huiai Hospital, Guanzhou, Guangdong, China
🇨🇳Cancer canter of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
- Conditions
- Interventions
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2017-06-29
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT03204032
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
The Effective and Safety of Thalidomide in TI
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Xiao-Lin Yin
- Target Recruit Count
- 100
- Registration Number
- NCT03184844
- Locations
- 🇨🇳
NO.3 Hospital of the Chinese People's Liberation Army, Nanjing, Guangxi, China
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
- Conditions
- Interventions
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 93
- Registration Number
- NCT03122431
- Locations
- 🇧🇷
Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil
A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03069326
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 232
- Registration Number
- NCT03062800
- Locations
- 🇨🇳
Qilu hospital of Shandong University, Jinan, Shandong, China
Thalidomide Maintenance Treatment in DLBCL
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 226
- Registration Number
- NCT03016000
- Locations
- 🇨🇳
Ru Feng, Guangzhou, Guangdong, China
2015-12: a Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 50
- Registration Number
- NCT03004287
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.